Scarica l'app Stockscreener
8.25
1.20%
-0.10
Kyverna Therapeutics Inc Borsa (KYTX) Ultime notizie
Kyverna Therapeutics (NASDAQ:KYTX) Trading Down 7.3%Time to Sell? - MarketBeat
Miv-cel Earns RMAT Designation for Progressive Multiple Sclerosis - CGTLive®
Kyverna (KYTX) Latest Reading: Declines 5.03% to $8.50 in the Latest Session; Session Range View: the Session Ends Within the Reported Technical Boundaries in the Available RecordDay Trade Opportunities - vinanet.vn
KYTX Stock Soars After Hours: What’s Driving The Rally? - Stocktwits
Kyverna Therapeutics (NASDAQ:KYTX) Trading 6.7% HigherShould You Buy? - MarketBeat
AIGH Capital Management LLC Purchases Shares of 2,795,797 Kyverna Therapeutics, Inc. $KYTX - MarketBeat
Walleye Capital LLC Purchases New Shares in Kyverna Therapeutics, Inc. $KYTX - MarketBeat
KYTX Edges Higher: Kyverna Therapeutics Climbs 1.11% to $8.17Fibonacci Retracement - Vinanet
Q3 EPS Estimate for Kyverna Therapeutics Lifted by Analyst - MarketBeat
Kyverna Therapeutics (KYTX): Bain Capital fund reports 4.75% ownership stake - Stock Titan
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
KYTX Q1 2026 Earnings: Narrower-than-Expected Loss of -0.66 per Share Highlights Clinical-Stage Cost Discipline - vinanet.vn
Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval (NASDAQ:KYTX) - Seeking Alpha
H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Kyverna Therapeutics (KYTX) Earnings Date and Reports 2026 $KYTX - MarketBeat
Kyverna Therapeutics (NASDAQ:KYTX) Releases Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Kyverna Therapeutics narrows Q2 losses, secures RMAT for miv-cel - scanx.trade
Kyverna Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Kyverna Therapeutics Announces Q2 2026 Financial Results and Operational Update - Kalkine Media
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results - The Manila Times
KYTX: Q2 2026 net loss narrowed to $38.3M as miv-cel advanced toward commercialization - TradingView
Kyverna Therapeutics (KYTX) deepens pipeline with SPS BLA, H1 2026 loss narrows - Stock Titan
Renaissance Technologies LLC Grows Stock Holdings in Kyverna Therapeutics, Inc. $KYTX - MarketBeat
Kyverna Therapeutics, Inc. expected to post a loss of 68 cents a shareEarnings Preview - TradingView
Kyverna Therapeutics Inc (KYTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kyverna Therapeutics (KYTX) Gains 1.44% to $7.75, Holding Above Key SupportDay Trade Opportunities - vinanet.vn
Kyverna Therapeutics and ElevateBio Sign Commercial Manufacturing Agreement for Miv-Cel - BioPharm International
Kyverna Therapeutics (KYTX) Expected to Post Quarterly Earnings on Tuesday - MarketBeat
BlackRock (NYSE: BLK) discloses 5.1% beneficial stake in Kyverna Therapeutics (KYTX) - Stock Titan
ElevateBio inks deal to supply Kyverna’s CAR T-cell therapy for gMG - Myasthenia Gravis News
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel - BioInformant
Kyverna Therapeutics Inc (KYTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kyverna and ElevateBio collaborate on miv-cel - The Pharma Letter
William Blair Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating - Moomoo
Kyverna, ElevateBio Ink Manufacturing Agreement for Miv-Cel Supply - Contract Pharma
KYTX|Kyverna Therapeutics Inc|Price:7.890|Chg%:+0.480 - TradingKey
Kyverna Therapeutics, Inc. and Elevatebio, Inc. Enter into Commercial Manufacturing and Supply Agreement for Miv-Cel - marketscreener.com
Kyverna, ElevateBio sign manufacturing pact for miv-cel supply - Investing.com
Kyverna Therapeutics and ElevateBio Secure Scalable Manufacturing Agreement to Launch First CAR T-Cell Therapy for Autoimmune Diseases - Minichart
Kyverna Therapeutics Inc (KYTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kyverna Therapeutics Inc (KYTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kyverna Therapeutics Inc (KYTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kyverna Therapeutics Inc (KYTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Kyverna Therapeutics Inc (KYTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Kyverna Therapeutics Market Sentiment - Benzinga España
Kyverna Therapeutics Inc (KYTX) Cash Flow - TradingKey
KYTX|Kyverna Therapeutics Inc|Price:7.910|Chg%:+0.500 - TradingKey
KYTX|Kyverna Therapeutics Inc|Price:7.300|Chg%:-0.190 - TradingKey
Kyverna Therapeutics Inc (KYTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
KYTX|Kyverna Therapeutics Inc|Price:7.770|Chg%:+0.360 - TradingKey
Kyverna Therapeutics, Inc. Revenue Breakdown – NASDAQ:KYTX - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Wells Fargo Maintains Kyverna Therapeutics (KYTX) Overweight Recommendation - MSN
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Kyverna Therapeutics (KYTX) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Nadia Dac Net Worth (2026) - GuruFocus
Kyverna Therapeutics (KYTX) Wells Fargo 20th Annual Healthcare Conference 2025 summary - Quartr
BIO 2026: Catching Up With Vaxart, Aphaia, Connect Biopharma, Kyverna And Chugai - insights.citeline.com
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):